+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Antimicrobial Resistance Market By Drug Class, By Pathogen, By Indication, By Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2023-2032

  • PDF Icon

    Report

  • 389 Pages
  • August 2023
  • Region: Global
  • Allied Market Research
  • ID: 5894372
UP TO OFF until Nov 15th 2024
The antimicrobial resistance market was valued at $4.6 billion in 2022 and is estimated to reach $9.5 billion by 2032, exhibiting a CAGR of 7.6% from 2023 to 2032. Antimicrobial resistance (AMR), also known as drug resistance is the resistance developed by the bacteria, viruses, fungi, and parasites to the available antimicrobial drugs over a period. It is a comprehensive concept and often encompasses resistance to antibacterial, antiviral, antiparasitic, and antifungal drugs. The microorganisms which become resistant to most of the antimicrobials are often referred to as superbugs. Few examples of superbugs include MRSA (methicillin-resistant staphylococcus aureus), Clostridium difficile (C. diff), and the bacteria that cause multi-drug-resistant tuberculosis.

Resistance to antimicrobials often develops in microorganisms over time because of genetic changes that occur during their reproductive cycles. Changes in the DNA may result in barriers that prevent antimicrobials from reaching the cell of microbe or may develop the ability to create enzymes that are able to counteract effects of the antimicrobial.

Antimicrobial resistance is significantly influenced by the overuse of antibiotics. Resistance to antimicrobials is heavily influenced by the excessive use of antibiotics. There is a higher chance of leaving behind resilient microbes when antibiotic treatments are too short, weak, or inappropriate for the specific infection. Moreover, antibiotics are often prescribed unnecessarily for viral infections such as colds, flu, or mild illnesses, which do not respond to antibiotics. Overprescribing leads to the unnecessary exposure of bacteria to these drugs, increasing the risk of resistance.

In addition, repeated exposure of microbes to antimicrobials, as well as contact with other already resistant microbes, provides numerous opportunities for resistance to develop and spread. Therefore, it is crucial to use antimicrobials appropriately to minimize the risk of antimicrobial resistance.

Furthermore, the rise in government initiatives to combat this antimicrobial resistance is the key factor which boosts the growth of the antimicrobial resistance market. For instance, the Global Antimicrobial Resistance Research & Development (AMR R&D) Hub is a collaboration of governments, non-governmental donor organizations, and intergovernmental organizations that use a One Health strategy to solve difficulties and increase coordination and collaboration in global AMR R&D.

On the other hand, the high cost of these novel therapeutics is expected to act as a restraint to the market growth. R&D of these antimicrobial candidates is expensive leading to higher cost of the products. This becomes difficult for people in lower-income countries to afford high-cost advanced antimicrobials and avoid antimicrobial resistance which may hinder market growth to some extent.

However, robust pipeline of antibiotic treatments to combat antimicrobial resistance is expected to offer lucrative opportunities for the growth of the market during the forecast period. Researchers and pharmaceutical companies have developed innovative therapies and treatments to combat antimicrobial resistance, providing potential new treatment options. In addition, the development of innovative antibiotics offers healthcare providers a wider range of treatment options. Having multiple effective antibiotics with different mechanisms of action can improve the chances of successfully treating infections, even those caused by highly resistant bacteria. This is expected to effectively overcome the threat of antimicrobial resistance and thus contribute to market growth during the forecast period.

The antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others.

On the basis of on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major key players that operate in the global antimicrobial resistance market are Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the antimicrobial resistance market analysis from 2022 to 2032 to identify the prevailing antimicrobial resistance market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the antimicrobial resistance market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global antimicrobial resistance market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly update (only available with the purchase of an enterprise license)
  • 5 additional company profiles of your choice, pre- or post-purchase, as a free update.
  • Free updated version (once released) with the purchase of a 1-5 or enterprise user license.
  • 16 analyst hours of support (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% free customization (in case the scope or segment of the report does not match your requirements, 20% is equivalent to 3 working days of free work, applicable once)
  • Free data pack (Excel version) with the purchase of a 1-5 or enterprise user license.
  • Free report update, if the report is 6-12 months old or older.
  • 24-hour priority response
  • Free industry updates and white papers.

Key Market Segments

By Indication

  • Complicated Urinary Tract Infections (cUTI)
  • Blood stream infections
  • Acute bacterial skin and skin structure infections (ABSSSI)
  • Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
  • Community acquired pneumonia (CAP)
  • Others

By Drug Class

  • Combination therapies
  • Tetracyclines
  • Cephalosporins
  • Glycopeptides and Lipoglycopeptides
  • Oxazolidinones
  • Others

By Mechanism of Action

  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • Others

By Pathogen

  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Staphylococcus aureus
  • Enterococcus Spp
  • Others
  • Escherichia coli

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • Pfizer Inc.
  • Cumberland Pharmaceuticals
  • Acurx Pharmaceuticals, Inc.
  • Paratek Pharmaceuticals Inc
  • Alkem Laboratories Ltd.
  • Nabriva Therapeutics plc
  • Innoviva, Inc
  • Basilea Pharmaceutica Ltd
  • Wockhardt Limited.
  • Merck & Co., Inc.

 

Please note:

  • Online Access price format is valid for 60 days access. Printing is not enabled.
  • PDF Single and Enterprise price formats enable printing.

 

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Low bargaining power of suppliers
3.3.2. Low threat of new entrants
3.3.3. Low threat of substitutes
3.3.4. Low intensity of rivalry
3.3.5. Low bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Overuse and misuse of antibiotics
3.4.1.2. Rise in prevalence of antimicrobial resistance bacterial infections
3.4.1.3. Growth in burden of antimicrobial resistance
3.4.2. Restraints
3.4.2.1. Global shortage of innovative antibiotics to combat antimicrobial resistance
3.4.3. Opportunities
3.4.3.1. Surge in initiative to tackle antimicrobial resistance (AMR) globally
CHAPTER 4: ANTIMICROBIAL RESISTANCE MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Combination therapies
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Tetracyclines
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cephalosporins
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Glycopeptides and Lipoglycopeptides
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Oxazolidinones
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
4.7. Others
4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market share analysis by country
CHAPTER 5: ANTIMICROBIAL RESISTANCE MARKET, BY PATHOGEN
5.1. Overview
5.1.1. Market size and forecast
5.2. Escherichia coli
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Klebsiella pneumoniae
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Pseudomonas aeruginosa
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
5.5. Staphylococcus aureus
5.5.1. Key market trends, growth factors and opportunities
5.5.2. Market size and forecast, by region
5.5.3. Market share analysis by country
5.6. Enterococcus Spp
5.6.1. Key market trends, growth factors and opportunities
5.6.2. Market size and forecast, by region
5.6.3. Market share analysis by country
5.7. Others
5.7.1. Key market trends, growth factors and opportunities
5.7.2. Market size and forecast, by region
5.7.3. Market share analysis by country
CHAPTER 6: ANTIMICROBIAL RESISTANCE MARKET, BY INDICATION
6.1. Overview
6.1.1. Market size and forecast
6.2. Complicated Urinary Tract Infections (cUTI)
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Blood stream infections
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Acute bacterial skin and skin structure infections (ABSSSI)
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
6.5. Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP)
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by region
6.5.3. Market share analysis by country
6.6. Community acquired pneumonia (CAP)
6.6.1. Key market trends, growth factors and opportunities
6.6.2. Market size and forecast, by region
6.6.3. Market share analysis by country
6.7. Others
6.7.1. Key market trends, growth factors and opportunities
6.7.2. Market size and forecast, by region
6.7.3. Market share analysis by country
CHAPTER 7: ANTIMICROBIAL RESISTANCE MARKET, BY MECHANISM OF ACTION
7.1. Overview
7.1.1. Market size and forecast
7.2. Protein Synthesis Inhibitors
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by region
7.2.3. Market share analysis by country
7.3. Cell Wall Synthesis Inhibitors
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by region
7.3.3. Market share analysis by country
7.4. Others
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by region
7.4.3. Market share analysis by country
CHAPTER 8: ANTIMICROBIAL RESISTANCE MARKET, BY REGION
8.1. Overview
8.1.1. Market size and forecast By Region
8.2. North America
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast, by Drug Class
8.2.3. Market size and forecast, by Pathogen
8.2.4. Market size and forecast, by Indication
8.2.5. Market size and forecast, by Mechanism of Action
8.2.6. Market size and forecast, by country
8.2.6.1. U.S.
8.2.6.1.1. Market size and forecast, by Drug Class
8.2.6.1.2. Market size and forecast, by Pathogen
8.2.6.1.3. Market size and forecast, by Indication
8.2.6.1.4. Market size and forecast, by Mechanism of Action
8.2.6.2. Canada
8.2.6.2.1. Market size and forecast, by Drug Class
8.2.6.2.2. Market size and forecast, by Pathogen
8.2.6.2.3. Market size and forecast, by Indication
8.2.6.2.4. Market size and forecast, by Mechanism of Action
8.2.6.3. Mexico
8.2.6.3.1. Market size and forecast, by Drug Class
8.2.6.3.2. Market size and forecast, by Pathogen
8.2.6.3.3. Market size and forecast, by Indication
8.2.6.3.4. Market size and forecast, by Mechanism of Action
8.3. Europe
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast, by Drug Class
8.3.3. Market size and forecast, by Pathogen
8.3.4. Market size and forecast, by Indication
8.3.5. Market size and forecast, by Mechanism of Action
8.3.6. Market size and forecast, by country
8.3.6.1. Germany
8.3.6.1.1. Market size and forecast, by Drug Class
8.3.6.1.2. Market size and forecast, by Pathogen
8.3.6.1.3. Market size and forecast, by Indication
8.3.6.1.4. Market size and forecast, by Mechanism of Action
8.3.6.2. France
8.3.6.2.1. Market size and forecast, by Drug Class
8.3.6.2.2. Market size and forecast, by Pathogen
8.3.6.2.3. Market size and forecast, by Indication
8.3.6.2.4. Market size and forecast, by Mechanism of Action
8.3.6.3. UK
8.3.6.3.1. Market size and forecast, by Drug Class
8.3.6.3.2. Market size and forecast, by Pathogen
8.3.6.3.3. Market size and forecast, by Indication
8.3.6.3.4. Market size and forecast, by Mechanism of Action
8.3.6.4. Italy
8.3.6.4.1. Market size and forecast, by Drug Class
8.3.6.4.2. Market size and forecast, by Pathogen
8.3.6.4.3. Market size and forecast, by Indication
8.3.6.4.4. Market size and forecast, by Mechanism of Action
8.3.6.5. Spain
8.3.6.5.1. Market size and forecast, by Drug Class
8.3.6.5.2. Market size and forecast, by Pathogen
8.3.6.5.3. Market size and forecast, by Indication
8.3.6.5.4. Market size and forecast, by Mechanism of Action
8.3.6.6. Rest of Europe
8.3.6.6.1. Market size and forecast, by Drug Class
8.3.6.6.2. Market size and forecast, by Pathogen
8.3.6.6.3. Market size and forecast, by Indication
8.3.6.6.4. Market size and forecast, by Mechanism of Action
8.4. Asia-Pacific
8.4.1. Key market trends, growth factors and opportunities
8.4.2. Market size and forecast, by Drug Class
8.4.3. Market size and forecast, by Pathogen
8.4.4. Market size and forecast, by Indication
8.4.5. Market size and forecast, by Mechanism of Action
8.4.6. Market size and forecast, by country
8.4.6.1. Japan
8.4.6.1.1. Market size and forecast, by Drug Class
8.4.6.1.2. Market size and forecast, by Pathogen
8.4.6.1.3. Market size and forecast, by Indication
8.4.6.1.4. Market size and forecast, by Mechanism of Action
8.4.6.2. China
8.4.6.2.1. Market size and forecast, by Drug Class
8.4.6.2.2. Market size and forecast, by Pathogen
8.4.6.2.3. Market size and forecast, by Indication
8.4.6.2.4. Market size and forecast, by Mechanism of Action
8.4.6.3. India
8.4.6.3.1. Market size and forecast, by Drug Class
8.4.6.3.2. Market size and forecast, by Pathogen
8.4.6.3.3. Market size and forecast, by Indication
8.4.6.3.4. Market size and forecast, by Mechanism of Action
8.4.6.4. Australia
8.4.6.4.1. Market size and forecast, by Drug Class
8.4.6.4.2. Market size and forecast, by Pathogen
8.4.6.4.3. Market size and forecast, by Indication
8.4.6.4.4. Market size and forecast, by Mechanism of Action
8.4.6.5. South Korea
8.4.6.5.1. Market size and forecast, by Drug Class
8.4.6.5.2. Market size and forecast, by Pathogen
8.4.6.5.3. Market size and forecast, by Indication
8.4.6.5.4. Market size and forecast, by Mechanism of Action
8.4.6.6. Rest of Asia-Pacific
8.4.6.6.1. Market size and forecast, by Drug Class
8.4.6.6.2. Market size and forecast, by Pathogen
8.4.6.6.3. Market size and forecast, by Indication
8.4.6.6.4. Market size and forecast, by Mechanism of Action
8.5. LAMEA
8.5.1. Key market trends, growth factors and opportunities
8.5.2. Market size and forecast, by Drug Class
8.5.3. Market size and forecast, by Pathogen
8.5.4. Market size and forecast, by Indication
8.5.5. Market size and forecast, by Mechanism of Action
8.5.6. Market size and forecast, by country
8.5.6.1. Brazil
8.5.6.1.1. Market size and forecast, by Drug Class
8.5.6.1.2. Market size and forecast, by Pathogen
8.5.6.1.3. Market size and forecast, by Indication
8.5.6.1.4. Market size and forecast, by Mechanism of Action
8.5.6.2. Saudi Arabia
8.5.6.2.1. Market size and forecast, by Drug Class
8.5.6.2.2. Market size and forecast, by Pathogen
8.5.6.2.3. Market size and forecast, by Indication
8.5.6.2.4. Market size and forecast, by Mechanism of Action
8.5.6.3. South Africa
8.5.6.3.1. Market size and forecast, by Drug Class
8.5.6.3.2. Market size and forecast, by Pathogen
8.5.6.3.3. Market size and forecast, by Indication
8.5.6.3.4. Market size and forecast, by Mechanism of Action
8.5.6.4. Rest of LAMEA
8.5.6.4.1. Market size and forecast, by Drug Class
8.5.6.4.2. Market size and forecast, by Pathogen
8.5.6.4.3. Market size and forecast, by Indication
8.5.6.4.4. Market size and forecast, by Mechanism of Action
CHAPTER 9: COMPETITIVE LANDSCAPE
9.1. Introduction
9.2. Top winning strategies
9.3. Product Mapping of Top 10 Players
9.4. Competitive Dashboard
9.5. Competitive Heatmap
9.6. Top player positioning, 2022
CHAPTER 10: COMPANY PROFILES
10.1. Alkem Laboratories Ltd.
10.1.1. Company overview
10.1.2. Key Executives
10.1.3. Company snapshot
10.1.4. Operating business segments
10.1.5. Product portfolio
10.1.6. Business performance
10.1.7. Key strategic moves and developments
10.2. Pfizer Inc.
10.2.1. Company overview
10.2.2. Key Executives
10.2.3. Company snapshot
10.2.4. Operating business segments
10.2.5. Product portfolio
10.2.6. Business performance
10.2.7. Key strategic moves and developments
10.3. Acurx Pharmaceuticals, Inc.
10.3.1. Company overview
10.3.2. Key Executives
10.3.3. Company snapshot
10.3.4. Operating business segments
10.3.5. Product portfolio
10.4. Basilea Pharmaceutica Ltd
10.4.1. Company overview
10.4.2. Key Executives
10.4.3. Company snapshot
10.4.4. Operating business segments
10.4.5. Product portfolio
10.4.6. Business performance
10.5. Cumberland Pharmaceuticals
10.5.1. Company overview
10.5.2. Key Executives
10.5.3. Company snapshot
10.5.4. Operating business segments
10.5.5. Product portfolio
10.5.6. Business performance
10.5.7. Key strategic moves and developments
10.6. Wockhardt Limited.
10.6.1. Company overview
10.6.2. Key Executives
10.6.3. Company snapshot
10.6.4. Operating business segments
10.6.5. Product portfolio
10.6.6. Business performance
10.7. Paratek Pharmaceuticals Inc
10.7.1. Company overview
10.7.2. Key Executives
10.7.3. Company snapshot
10.7.4. Operating business segments
10.7.5. Product portfolio
10.7.6. Business performance
10.8. Nabriva Therapeutics plc
10.8.1. Company overview
10.8.2. Key Executives
10.8.3. Company snapshot
10.8.4. Operating business segments
10.8.5. Product portfolio
10.8.6. Business performance
10.8.7. Key strategic moves and developments
10.9. Innoviva, Inc
10.9.1. Company overview
10.9.2. Key Executives
10.9.3. Company snapshot
10.9.4. Operating business segments
10.9.5. Product portfolio
10.9.6. Business performance
10.10. Merck & Co., Inc.
10.10.1. Company overview
10.10.2. Key Executives
10.10.3. Company snapshot
10.10.4. Operating business segments
10.10.5. Product portfolio
10.10.6. Business performance
List of Tables
Table 01. Global Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 02. Antimicrobial Resistance Market for Combination Therapies, by Region, 2022-2032 ($Million)
Table 03. Antimicrobial Resistance Market for Tetracyclines, by Region, 2022-2032 ($Million)
Table 04. Antimicrobial Resistance Market for Cephalosporins, by Region, 2022-2032 ($Million)
Table 05. Antimicrobial Resistance Market for Glycopeptides and Lipoglycopeptides, by Region, 2022-2032 ($Million)
Table 06. Antimicrobial Resistance Market for Oxazolidinones, by Region, 2022-2032 ($Million)
Table 07. Antimicrobial Resistance Market for Others, by Region, 2022-2032 ($Million)
Table 08. Global Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 09. Antimicrobial Resistance Market for Escherichia Coli, by Region, 2022-2032 ($Million)
Table 10. Antimicrobial Resistance Market for Klebsiella Pneumoniae, by Region, 2022-2032 ($Million)
Table 11. Antimicrobial Resistance Market for Pseudomonas Aeruginosa, by Region, 2022-2032 ($Million)
Table 12. Antimicrobial Resistance Market for Staphylococcus Aureus, by Region, 2022-2032 ($Million)
Table 13. Antimicrobial Resistance Market for Enterococcus Spp, by Region, 2022-2032 ($Million)
Table 14. Antimicrobial Resistance Market for Others, by Region, 2022-2032 ($Million)
Table 15. Global Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 16. Antimicrobial Resistance Market for Complicated Urinary Tract Infections (Cuti), by Region, 2022-2032 ($Million)
Table 17. Antimicrobial Resistance Market for Blood Stream Infections, by Region, 2022-2032 ($Million)
Table 18. Antimicrobial Resistance Market for Acute Bacterial Skin and Skin Structure Infections (Absssi), by Region, 2022-2032 ($Million)
Table 19. Antimicrobial Resistance Market for Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (Habp and Vabp), by Region, 2022-2032 ($Million)
Table 20. Antimicrobial Resistance Market for Community Acquired Pneumonia (Cap), by Region, 2022-2032 ($Million)
Table 21. Antimicrobial Resistance Market for Others, by Region, 2022-2032 ($Million)
Table 22. Global Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 23. Antimicrobial Resistance Market for Protein Synthesis Inhibitors, by Region, 2022-2032 ($Million)
Table 24. Antimicrobial Resistance Market for Cell Wall Synthesis Inhibitors, by Region, 2022-2032 ($Million)
Table 25. Antimicrobial Resistance Market for Others, by Region, 2022-2032 ($Million)
Table 26. Antimicrobial Resistance Market, by Region, 2022-2032 ($Million)
Table 27. North America Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 28. North America Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 29. North America Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 30. North America Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 31. North America Antimicrobial Resistance Market, by Country, 2022-2032 ($Million)
Table 32. U.S. Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 33. U.S. Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 34. U.S. Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 35. U.S. Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 36. Canada Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 37. Canada Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 38. Canada Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 39. Canada Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 40. Mexico Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 41. Mexico Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 42. Mexico Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 43. Mexico Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 44. Europe Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 45. Europe Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 46. Europe Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 47. Europe Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 48. Europe Antimicrobial Resistance Market, by Country, 2022-2032 ($Million)
Table 49. Germany Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 50. Germany Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 51. Germany Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 52. Germany Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 53. France Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 54. France Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 55. France Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 56. France Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 57. UK Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 58. UK Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 59. UK Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 60. UK Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 61. Italy Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 62. Italy Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 63. Italy Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 64. Italy Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 65. Spain Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 66. Spain Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 67. Spain Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 68. Spain Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 69. Rest of Europe Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 70. Rest of Europe Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 71. Rest of Europe Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 72. Rest of Europe Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 73. Asia-Pacific Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 74. Asia-Pacific Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 75. Asia-Pacific Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 76. Asia-Pacific Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 77. Asia-Pacific Antimicrobial Resistance Market, by Country, 2022-2032 ($Million)
Table 78. Japan Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 79. Japan Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 80. Japan Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 81. Japan Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 82. China Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 83. China Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 84. China Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 85. China Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 86. India Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 87. India Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 88. India Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 89. India Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 90. Australia Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 91. Australia Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 92. Australia Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 93. Australia Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 94. South Korea Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 95. South Korea Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 96. South Korea Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 97. South Korea Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 98. Rest of Asia-Pacific Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 99. Rest of Asia-Pacific Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 100. Rest of Asia-Pacific Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 101. Rest of Asia-Pacific Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 102. LAMEA Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 103. LAMEA Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 104. LAMEA Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 105. LAMEA Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 106. LAMEA Antimicrobial Resistance Market, by Country, 2022-2032 ($Million)
Table 107. Brazil Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 108. Brazil Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 109. Brazil Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 110. Brazil Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 111. Saudi Arabia Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 112. Saudi Arabia Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 113. Saudi Arabia Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 114. Saudi Arabia Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 115. South Africa Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 116. South Africa Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 117. South Africa Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 118. South Africa Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 119. Rest of LAMEA Antimicrobial Resistance Market, by Drug Class, 2022-2032 ($Million)
Table 120. Rest of LAMEA Antimicrobial Resistance Market, by Pathogen, 2022-2032 ($Million)
Table 121. Rest of LAMEA Antimicrobial Resistance Market, by Indication, 2022-2032 ($Million)
Table 122. Rest of LAMEA Antimicrobial Resistance Market, by Mechanism of Action, 2022-2032 ($Million)
Table 123. Alkem Laboratories Ltd.: Key Executives
Table 124. Alkem Laboratories Ltd.: Company Snapshot
Table 125. Alkem Laboratories Ltd.: Product Segments
Table 126. Alkem Laboratories Ltd.: Product Portfolio
Table 127. Alkem Laboratories Ltd.: Key Stratergies
Table 128. Pfizer Inc.: Key Executives
Table 129. Pfizer Inc.: Company Snapshot
Table 130. Pfizer Inc.: Product Segments
Table 131. Pfizer Inc.: Product Portfolio
Table 132. Pfizer Inc.: Key Stratergies
Table 133. Acurx Pharmaceuticals, Inc.: Key Executives
Table 134. Acurx Pharmaceuticals, Inc.: Company Snapshot
Table 135. Acurx Pharmaceuticals, Inc.: Product Segments
Table 136. Acurx Pharmaceuticals, Inc.: Product Portfolio
Table 137. Basilea Pharmaceutica Ltd.: Key Executives
Table 138. Basilea Pharmaceutica Ltd.: Company Snapshot
Table 139. Basilea Pharmaceutica Ltd.: Product Segments
Table 140. Basilea Pharmaceutica Ltd.: Product Portfolio
Table 141. Cumberland Pharmaceuticals: Key Executives
Table 142. Cumberland Pharmaceuticals: Company Snapshot
Table 143. Cumberland Pharmaceuticals: Product Segments
Table 144. Cumberland Pharmaceuticals: Product Portfolio
Table 145. Cumberland Pharmaceuticals: Key Stratergies
Table 146. Wockhardt Limited.: Key Executives
Table 147. Wockhardt Limited.: Company Snapshot
Table 148. Wockhardt Limited.: Product Segments
Table 149. Wockhardt Limited.: Product Portfolio
Table 150. Paratek Pharmaceuticals Inc.: Key Executives
Table 151. Paratek Pharmaceuticals Inc.: Company Snapshot
Table 152. Paratek Pharmaceuticals Inc.: Product Segments
Table 153. Paratek Pharmaceuticals Inc.: Product Portfolio
Table 154. Nabriva Therapeutics PLC: Key Executives
Table 155. Nabriva Therapeutics PLC: Company Snapshot
Table 156. Nabriva Therapeutics PLC: Product Segments
Table 157. Nabriva Therapeutics PLC: Product Portfolio
Table 158. Nabriva Therapeutics PLC: Key Stratergies
Table 159. Innoviva, Inc.: Key Executives
Table 160. Innoviva, Inc.: Company Snapshot
Table 161. Innoviva, Inc.: Product Segments
Table 162. Innoviva, Inc.: Product Portfolio
Table 163. Merck & Co. Inc.: Key Executives
Table 164. Merck & Co. Inc.: Company Snapshot
Table 165. Merck & Co. Inc.: Product Segments
Table 166. Merck & Co. Inc.: Product Portfolio
List of Figures
Figure 01. Antimicrobial Resistance Market, 2022-2032
Figure 02. Segmentation of Antimicrobial Resistance Market, 2022-2032
Figure 03. Top Investment Pockets in Antimicrobial Resistance Market (2023-2032)
Figure 04. Low Bargaining Power of Suppliers
Figure 05. Low Threat of New Entrants
Figure 06. Low Threat of Substitutes
Figure 07. Low Intensity of Rivalry
Figure 08. Low Bargaining Power of Buyers
Figure 09. Global Antimicrobial Resistance Market:Drivers, Restraints and Opportunities
Figure 10. Antimicrobial Resistance Market, by Drug Class, 2022 and 2032 (%)
Figure 11. Comparative Share Analysis of Antimicrobial Resistance Market for Combination Therapies, by Country 2022 and 2032 (%)
Figure 12. Comparative Share Analysis of Antimicrobial Resistance Market for Tetracyclines, by Country 2022 and 2032 (%)
Figure 13. Comparative Share Analysis of Antimicrobial Resistance Market for Cephalosporins, by Country 2022 and 2032 (%)
Figure 14. Comparative Share Analysis of Antimicrobial Resistance Market for Glycopeptides and Lipoglycopeptides, by Country 2022 and 2032 (%)
Figure 15. Comparative Share Analysis of Antimicrobial Resistance Market for Oxazolidinones, by Country 2022 and 2032 (%)
Figure 16. Comparative Share Analysis of Antimicrobial Resistance Market for Others, by Country 2022 and 2032 (%)
Figure 17. Antimicrobial Resistance Market, by Pathogen, 2022 and 2032 (%)
Figure 18. Comparative Share Analysis of Antimicrobial Resistance Market for Escherichia Coli, by Country 2022 and 2032 (%)
Figure 19. Comparative Share Analysis of Antimicrobial Resistance Market for Klebsiella Pneumoniae, by Country 2022 and 2032 (%)
Figure 20. Comparative Share Analysis of Antimicrobial Resistance Market for Pseudomonas Aeruginosa, by Country 2022 and 2032 (%)
Figure 21. Comparative Share Analysis of Antimicrobial Resistance Market for Staphylococcus Aureus, by Country 2022 and 2032 (%)
Figure 22. Comparative Share Analysis of Antimicrobial Resistance Market for Enterococcus Spp, by Country 2022 and 2032 (%)
Figure 23. Comparative Share Analysis of Antimicrobial Resistance Market for Others, by Country 2022 and 2032 (%)
Figure 24. Antimicrobial Resistance Market, by Indication, 2022 and 2032 (%)
Figure 25. Comparative Share Analysis of Antimicrobial Resistance Market for Complicated Urinary Tract Infections (Cuti), by Country 2022 and 2032 (%)
Figure 26. Comparative Share Analysis of Antimicrobial Resistance Market for Blood Stream Infections, by Country 2022 and 2032 (%)
Figure 27. Comparative Share Analysis of Antimicrobial Resistance Market for Acute Bacterial Skin and Skin Structure Infections (Absssi), by Country 2022 and 2032 (%)
Figure 28. Comparative Share Analysis of Antimicrobial Resistance Market for Hospital Acquired Bacterial Pneumonia and Ventilator Acquired Bacterial Pneumonia (Habp and Vabp), by Country 2022 and 2032 (%)
Figure 29. Comparative Share Analysis of Antimicrobial Resistance Market for Community Acquired Pneumonia (Cap), by Country 2022 and 2032 (%)
Figure 30. Comparative Share Analysis of Antimicrobial Resistance Market for Others, by Country 2022 and 2032 (%)
Figure 31. Antimicrobial Resistance Market, by Mechanism of Action, 2022 and 2032 (%)
Figure 32. Comparative Share Analysis of Antimicrobial Resistance Market for Protein Synthesis Inhibitors, by Country 2022 and 2032 (%)
Figure 33. Comparative Share Analysis of Antimicrobial Resistance Market for Cell Wall Synthesis Inhibitors, by Country 2022 and 2032 (%)
Figure 34. Comparative Share Analysis of Antimicrobial Resistance Market for Others, by Country 2022 and 2032 (%)
Figure 35. Antimicrobial Resistance Market by Region, 2022 and 2032 (%)
Figure 36. U.S. Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 37. Canada Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 38. Mexico Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 39. Germany Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 40. France Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 41. UK Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 42. Italy Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 43. Spain Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 44. Rest of Europe Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 45. Japan Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 46. China Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 47. India Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 48. Australia Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 49. South Korea Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 50. Rest of Asia-Pacific Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 51. Brazil Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 52. Saudi Arabia Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 53. South Africa Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 54. Rest of LAMEA Antimicrobial Resistance Market, 2022-2032 ($Million)
Figure 55. Top Winning Strategies, by Year (2020-2023)
Figure 56. Top Winning Strategies, by Development (2020-2023)
Figure 57. Top Winning Strategies, by Company (2020-2023)
Figure 58. Product Mapping of Top 10 Players
Figure 59. Competitive Dashboard
Figure 60. Competitive Heatmap: Antimicrobial Resistance Market
Figure 61. Top Player Positioning, 2022
Figure 62. Alkem Laboratories Ltd.: Net Revenue, 2020-2022 ($Million)
Figure 63. Alkem Laboratories Ltd.: Revenue Share by Region, 2022 (%)
Figure 64. Pfizer Inc.: Net Revenue, 2020-2022 ($Million)
Figure 65. Pfizer Inc.: Revenue Share by Segment, 2022 (%)
Figure 66. Pfizer Inc.: Revenue Share by Region, 2022 (%)
Figure 67. Basilea Pharmaceutica Ltd.: Net Revenue, 2020-2022 ($Million)
Figure 68. Basilea Pharmaceutica Ltd.: Revenue Share by Region, 2022 (%)
Figure 69. Cumberland Pharmaceuticals: Net Revenue, 2020-2022 ($Million)
Figure 70. Wockhardt Limited.: Net Revenue, 2021-2023 ($Million)
Figure 71. Wockhardt Limited.: Revenue Share by Region, 2023 (%)
Figure 72. Paratek Pharmaceuticals Inc.: Net Revenue, 2020-2022 ($Million)
Figure 73. Nabriva Therapeutics PLC: Net Revenue, 2020-2022 ($Million)
Figure 74. Innoviva, Inc.: Sales Revenue, 2020-2022 ($Million)
Figure 75. Merck & Co. Inc.: Net Revenue, 2020-2022 ($Million)
Figure 76. Merck & Co. Inc.: Revenue Share by Segment, 2022 (%)
Figure 77. Merck & Co. Inc.: Revenue Share by Region, 2022 (%)

Executive Summary

The antimicrobial resistance market is likely to experience a significant growth rate of 7.6% from 2023-2032 owing to increasing market demand from pharmaceutical sector

Antimicrobial resistance (AMR) is referred to the resistance developed by the microorganisms against the antibiotics over time. Antibiotics are often prescribed on a large scale for treatment of various bacterial infections and sometimes may be misused in treatment of viral infections. It has proved to be a global threat to the healthcare sector and is anticipated to grow at an alarming rate. Such misuse of antibiotics is the major factor that causes antimicrobial resistance among microorganisms. Thus, there is an urgent need for innovative antibiotics that are effective against these resistant bacteria, which propels the growth of the antimicrobial resistance market.

Key factors driving the growth of the antimicrobial resistance market are overuse and misuse of antibiotics, rise in prevalence of antimicrobial resistance bacterial infections and growth in burden of antimicrobial resistance. The burden of antimicrobial resistance is rising at an alarming rate which leads to severe negative effects on the healthcare systems around the globe.

In addition, according to the National Infection & Death Estimates for Antimicrobial Resistance, in the U. S., more than 2.8 million antimicrobial-resistant infections occur each year. Such huge burden of antimicrobial resistance leads to high treatment cost, increased mortality and morbidity, limited treatment options, and increased hospital stays. Also, the available treatment becomes ineffective which demands new and novel antibiotics that can overcome the AMR burden and propels the market growth.

Furthermore, the antimicrobial resistance market is expected to experience significant growth opportunities in developing regions over the next few years. The developing regions are working towards improving their healthcare infrastructure for which they need to set up and expand medical facilities, such as hospitals, clinics and outpatient care centers. This growth in medical facilities creates a need for novel antimicrobials, which are needed for effective patient care. This boosts market growth.

In addition, there is a surge in research and development activities to develop novel antibiotics medications which can be used in the treatment of resistant bacteria are anticipated to contribute to the market growth during the forecast period.

The antimicrobial resistance market is segmented on the antimicrobial resistance market is segmented on the basis of drug class, pathogen, indication, mechanism of action, and region. On the basis of drug class, the market is classified into combination therapies, tetracyclines, cephalosporins, glycopeptides and lipoglycopeptides, oxazolidinones and others. Based on on disease type, the market is segmented into complicated urinary tract infections (cUTI), blood stream infections, acute bacterial skin and skin structure infections (ABSSSI), hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), community acquired pneumonia (CAP) and Others.

On the basis of pathogen, the market is segmented into E. coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus, Enterococcus Spp and others. On the basis of mechanism of action, the market is categorized into protein synthesis inhibitors, cell wall synthesis inhibitors, and others. On the basis of region, the market is analyzed across North America (the U. S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

The key players profiled in the study include Alkem Laboratories Ltd, Innoviva, Inc., Pfizer Inc., Merck & Co., Inc., Acurx Pharmaceuticals, Inc., Basilea Pharmaceutica Ltd, Cumberland Pharmaceuticals Inc., Wockhardt Limited, Paratek Pharmaceuticals, Inc., and Nabriva Therapeutics plc. The players in the market have been actively engaged in the adoption of various strategies such as collaboration, funding, acquisition, product approval, product upgrade/development, agreement and product launch to remain competitive and gain an advantage over the competitors in the market.

For instance, in July 2020, Nabriva Therapeutics plc announced that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of Xenleta (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

Key Market Insights

By drug class, the combination therapies segment was the highest revenue contributor to the market whereas the others segment is anticipated to be the fastest growing segment during the forecast period.

By pathogen, the Escherichia coli segment dominated the global market whereas the Klebsiella pneumoniae segment is expected to be the fastest-growing segment during the forecast period.

By indication, the complicated urinary tract infections (cUTI) segment dominated the market in 2022, whereas the hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP & VABP) segment is anticipated to grow at a fastest rate during the forecast period.

By mechanism of action, the cell wall synthesis inhibitors segment dominated the market in 2022 and is anticipated to be the fastest growing segment during the forecast period.

Based on region, North America garnered the largest revenue share in 2022, and Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • Pfizer Inc.
  • Cumberland Pharmaceuticals
  • Acurx Pharmaceuticals, Inc.
  • Paratek Pharmaceuticals Inc
  • Alkem Laboratories Ltd.
  • Nabriva Therapeutics plc
  • Innoviva, Inc
  • Basilea Pharmaceutica Ltd
  • Wockhardt Limited.
  • Merck & Co., Inc.

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...